Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 4/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.43 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.43 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1552912 | 0.91 | RXRA (0.41) | EPHA2PDE4BERBB2EPHB4NR1H4 | |
| SCHEMBL14289468 | 0.89 | P2RX3 (0.40) | EPHA2ERBB2EPHB4NR1H4EPHX2 | |
| SCHEMBL1552792 | 0.88 | PREP (0.47) | EPHA2ERBB2EPHB4NR1H4EPHX2 | |
| SCHEMBL1552790 | 0.88 | PREP (0.47) | EPHA2ERBB2EPHB4NR1H4EPHX2 | |
| SCHEMBL1551985 | 0.88 | EPHA2 (0.47) | EPHA2PDE4BERBB2EPHB4NR1H4 | |
| SCHEMBL31076359 | 0.87 | EPHA2 (0.51) | EPHA2PDE4BERBB2EPHB4NR1H4 | |
| SCHEMBL1551943 | 0.86 | EPHA2 (0.46) | EPHA2PDE4BERBB2EPHB4NR1H4 | |
| SCHEMBL1552605 | 0.86 | EPHA2 (0.46) | EPHA2PDE4BERBB2EPHB4NR1H4 | |
| SCHEMBL1552680 | 0.86 | EPHA2 (0.50) | EPHA2PDE4BERBB2EPHB4NR1H4 | |
| SCHEMBL1552682 | 0.86 | EPHA2 (0.50) | EPHA2PDE4BERBB2EPHB4NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844026-B1 | MORPHOLINES AS 5HT2C AGONISTS | HOFFMANN LA ROCHE (CH) | 2011-04-27 | — | — | EP | disclosed |
| US-7323466-B2 | Morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMAN-LA ROCHE INC. (US) | 2008-01-29 | — | — | US | disclosed |
| EP-1844026-A2 | MORPHOLINES AS 5HT2C AGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-10-17 | — | — | EP | disclosed |
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HOFFMANN-LA ROCHE INC. | 2006-08-10 | — | — | US | disclosed |
| WO-2006077025-A2 | MORPHOLINES AS 5HT2C AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060178510-A1 | New morpholine derivatives as 5HT2C receptor agonists for the treatment of obesity | HTR2C, HTR1A, HTR1B | EPHA2 3530/4885PDE4B 514/4885ERBB2 1770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.